dichlorobis(1-benzyl-2-phenyl-1H-benzimidazole-κN³)cobalt(II) | 128179-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: dichlorobis(1-benzyl-2-phenyl-1H-benzimidazole-κN³)cobalt(II)
• 英文别名: {Co(II)(1-benzyl-2-phenylbenzimidazole)2Cl2}
• CAS: 128179-10-2
• 化学式: C₄₀H₃₂Cl₂CoN₄
• 分子量: 698.62
• InChiKey: MORUWAVEYOAXBI-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  dichlorobis(1-benzyl-2-phenyl-1H-benzimidazole-κN³)cobalt(II) 生成 cobalt(II) oxide
  参考文献：
  名称：

  Thermal and spectral studies of 1-benzyl-2- phenylbenzimidazole complexes of cobalt(II)

  摘要：

  DOI：

  10.1016/0040-6031(90)80121-e
• 作为产物：
  描述：

  苯甲醛 、 邻苯二胺 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 16.0h， 生成 dichlorobis(1-benzyl-2-phenyl-1H-benzimidazole-κN³)cobalt(II)
  参考文献：
  名称：

  以氯化物和1,2-二取代苯并咪唑为配体的四面体Co(II)配合物的单分子磁体行为和催化性能

  摘要：

  五种钴 ( II ) 配合物，式 [CoCl 2 (L n ) 2 ] [ 1与L 1 = 1-苄基-2-苯基-1 H-苯并咪唑，2与L 2 = 2-(呋喃-2-基) -1-(呋喃-2-基甲基)-1 H-苯并咪唑，3与L 3 = 1-(4-氯苄基)-2-(4-氯苯基)-1 H-苯并咪唑，4与L 4 = 1-( 2-甲氧基苄基)-2-(2-甲氧基苯基)-1 H-苯并咪唑和5与L 5= 2-(噻吩-2-基)-1-(噻吩-2-基甲基)-1 H-苯并咪唑]已被合成、光谱表征和低温磁学研究。1、3、4和5的晶体结构已通过单晶的 X 射线衍射确定。每个钴 ( II ) 离子在由两个氯阴离子和两个苯并咪唑配体构成的扭曲四面体环境中是四配位的。中性分子彼此分离良好，最短的分子间钴⋯钴距离大于 9.0 Å。1-5温度范围 2.0-300 K 的静态 (dc) 磁化率测量揭示了高温域中磁性非相互作用自旋四联体

  DOI：

  10.1039/d2dt01440h

文献信息

• Synthesis and evaluation of anticancer properties of novel benzimidazole ligand and their cobalt(II) and zinc(II) complexes against cancer cell lines A-2780 and DU-145
  作者：Ülkü Yılmaz、Suat Tekin、Nesrin Buğday、Kemal Yavuz、Hasan Küçükbay、Süleyman Sandal

  DOI：10.1016/j.ica.2019.118977

  日期：2019.9

  Eighteen new cobalt(II) or zinc(II) complexes of benzimidazole bearing 1-benzyl and 2-phenyl moieties were synthesized from the reaction of appropriate benzimidazole ligands and CoCl2 or ZnCl2. Their structural characterizations were done by IR, NMR (H-1, C-13) and UV-VIS spectrometers. Cytotoxic activities of eighteen new complexes and three benzimidazole ligands were determined using A-2780 (human ovarian) and DU-145 (human prostate) cell lines. Antitumor properties of all compounds were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell viability assay for the tested benzimidazole derivatives was performed and the LogIC(50) values of the compounds were calculated after a 24-hour treatment. All tested benzimidazole derivatives showed higher or comparable antitumor activity against A-2780 cell lines compared to the standard drug docetaxel with a LogIC(50) value of -0.81 mu M (p < 0.05). Eight of the examined compounds (1, 3, 5, 6, 7, 9, 10 and 13) showed high cytotoxic activity against A-2780 compared to the standard drug docetaxel. While the LogIC(50) of the docetaxel was -0.81 mu M for A-2780 cells at 24 h, the IC50 values of compounds 1, 3, 5, 6, 7, 9, 10 and 13 were - 0.97, -1.30, - 0.22, 0.13, - 0.16, - 0.73 and - 0.53 mu M, respectively. Three of the compounds 1, 18 and V showed high cytotoxic activity against DU-145 compared to docetaxel (p < 0.05). While the LogIC(50) of the docetaxel was -1.13 mu M for DU-145 cells at 24 h, the LogIC(50) values of compounds 1, 18 and V were 0.84, -0.38 and -0.66 mu M, respectively.